250 related articles for article (PubMed ID: 34888919)
1. Biologics for pediatric psoriasis: A systematic review and meta-analysis.
Sun HY; Phan K; Paller AS; Sebaratnam DF
Pediatr Dermatol; 2022 Jan; 39(1):42-48. PubMed ID: 34888919
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
3. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
4. Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis.
Golhen K; Winskill C; Theiler M; Buettcher M; Yeh YH; Zhang N; Welzel T; Pfister M
Front Med (Lausanne); 2022; 9():944208. PubMed ID: 36226155
[TBL] [Abstract][Full Text] [Related]
5. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.
Schwarz CW; Loft N; Rasmussen MK; Nissen CV; Dam TN; Ajgeiy KK; Egeberg A; Skov L
Acta Derm Venereol; 2021 Oct; 101(10):adv00579. PubMed ID: 34642768
[TBL] [Abstract][Full Text] [Related]
10. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
[TBL] [Abstract][Full Text] [Related]
11. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
12. Treatment of erythrodermic psoriasis with biologics: A systematic review.
Carrasquillo OY; Pabón-Cartagena G; Falto-Aizpurua LA; Santiago-Vázquez M; Cancel-Artau KJ; Arias-Berrios G; Martín-García RF
J Am Acad Dermatol; 2020 Jul; 83(1):151-158. PubMed ID: 32247872
[TBL] [Abstract][Full Text] [Related]
13. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biological agents for the treatment of pediatric patients with psoriasis: A bayesian analysis of six high-quality randomized controlled trials.
Cai XC; Ru Y; Liu L; Sun XY; Zhou YQ; Luo Y; Chen JL; Zhang M; Wang CX; Li B; Li X
Front Immunol; 2022; 13():896550. PubMed ID: 36081503
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
17. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
20. Switching biologics in children with psoriasis: Results from the BiPe cohort.
Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
